vaccine, virus and coronavirus

700 volunteers will test a coronavirus vaccine in Turkey

A possible coronavirus vaccine will be tested in 30,000 people in 172 countries, including Turkey. Its production could start in November.

Human trials as part of phase III of a possible coronavirus vaccine, jointly developed by pharmaceutical companies BioNTech and Pfizer, will be carried out between September and October in Turkey on 700 volunteers, according to information published in Turkish press.

According to the Turkish newspaper Milliyet, last July both companies launched phase III of the vaccine, which will be tested in a total of 30,000 people in 172 different countries. This phase, which is the one in which both the Russian vaccine and those of Cansino, Oxford or Modern are actually involved in, implies the inoculation of the vaccine in thousands of people to test its safety and its real efficacy, before being launched on the market.

In Turkey, volunteers have been enrolling at the Istanbul University School of Medicine and Cerrahpaşa Hospital to participate in the trial of this vaccine; candidates, who must be between 18 and 65 years old, will be selected from those who have not previously contracted the coronavirus, once the antibody test has been passed.

“The vaccine will be administered to the volunteers within a week. The next step will be to collect and analyze the data, and the production of the vaccine could begin in November,” Professor Tufan Tükek, dean of the School of Medicine of Istanbul University, explained to the Turkish newspaper, adding that both public and private institutions in Turkey are participating in the trials.

According to experts in Turkey, the volunteers for the tests of this possible vaccine against the coronavirus will be divided into two groups: a first group will be inoculated with the real vaccine, while the second will receive a placebo, a common practice in this type of vaccine trials with the aim of comparing the results.